Abstract
COP1 (constitutive photomorphogenic 1) is a p53-targeting E3 ubiquitin ligase. Recent studies have identified that COP1 is overexpressed in several cancer types, promoting tumor progression. This study investigated the expression and prognostic value of COP1 in primary gastric cancer. Using real-time quantitative PCR and western blotting on paired cancerous and matched adjacent noncancerous gastric tissues, the researchers found high COP1 mRNA and protein expression in tumor tissues. A significant negative correlation was observed between COP1 and p53 expression. Immunohistochemical analysis of 401 gastric cancer tissue blocks revealed that high COP1 expression significantly correlated with advanced T, M, and TNM stages, as well as poor overall survival. Cox regression analysis identified COP1 as an independent predictor of survival, suggesting its potential as a prognostic marker and therapeutic target.
Introduction
Gastric cancer remains a leading cause of cancer-related mortality worldwide, often characterized by late-stage diagnosis and a lack of precise prognostic indicators. The progression of this malignancy is driven by a complex interplay of oncogene activation and tumor suppressor inactivation. COP1 (also known as RFWD2), an E3 ubiquitin ligase, has emerged as a significant player in oncogenesis due to its ability to target the tumor suppressor p53 for degradation. While COP1's oncogenic role has been suggested in breast and ovarian cancers, its specific impact on gastric cancer prognosis and its clinical relationship with p53 required rigorous validation.
Methods
The researchers employed a multi-tiered experimental approach using samples from Sun Yat-sen University Cancer Center. The study utilized two primary patient cohorts: a fresh tissue cohort of 40 paired samples for immediate molecular analysis (RT-qPCR and Western blotting) and a historical cohort of 401 paraffin-embedded samples for long-term survival analysis. Immunohistochemistry (IHC) was used to map protein distribution and quantify expression levels across the larger cohort. Statistical significance was determined using Kaplan-Meier survival curves and Cox proportional-hazard regression models to evaluate COP1 as an independent prognostic factor.
Results
COP1 Overexpression in Gastric Cancer Tissues
Molecular analysis revealed that COP1 is markedly upregulated in gastric cancer tissues compared to matched adjacent normal tissues. RT-qPCR demonstrated significantly higher mRNA levels in 62.5% of tumor samples (P=0.030). Western blot analysis confirmed these findings at the protein level, showing significant elevation in 54.5% of cases (P=0.008), establishing COP1 as a consistently overexpressed marker in this cancer type.
Inverse Correlation Between COP1 and p53
A critical insight from this study is the strong negative correlation between COP1 and p53 expression. In clinical samples where COP1 protein levels were high, p53 levels were almost invariably low (r = -0.572, P = 0.005). This provides compelling clinical evidence for the biochemical model in which COP1 facilitates the degradation of the "guardian of the genome," p53, thereby promoting tumor survival and progression.
Clinical Significance and Prognostic Value
High COP1 expression was significantly associated with advanced clinicopathological features, including deeper tumor infiltration (T stage), distant metastasis (M stage), and higher overall TNM stage. Survival analysis demonstrated a stark disparity in outcomes: patients with high COP1 expression had a 5-year overall survival rate of 48.1%, compared to 71.0% for those with low expression (P < 0.001). Multivariate analysis confirmed that COP1 is an independent predictor of poor prognosis, providing information beyond standard staging.
Conclusion
This study establishes COP1 as a key oncogenic driver and a robust prognostic biomarker in gastric cancer. By facilitating p53 degradation, COP1 promotes aggressive tumor behavior and predicts significantly poorer patient survival. These findings suggest that COP1 could serve as a valuable target for novel therapeutic interventions, such as gene therapy or small molecule inhibitors, aimed at restoring p53 function in gastric cancer patients.
Summary updated